| 1 |
Pulanić D, Bátorová A, Bodó I, Červinek L, Ionita I, Lissitchkov T, Melikyan A, Podolak-Dawidziak M. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Ann Hematol 2023;102:715-27. [PMID: 36826482 DOI: 10.1007/s00277-023-05114-8] [Reference Citation Analysis]
|
| 2 |
Lisman T. Bleeding and thrombosis in cirrhosis. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00010-3] [Reference Citation Analysis]
|
| 3 |
Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology Am Soc Hematol Educ Program 2022;2022:296-302. [PMID: 36485111 DOI: 10.1182/hematology.2022000408] [Reference Citation Analysis]
|
| 4 |
La Mura V, Bitto N, Tripodi A. Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges. Expert Rev Hematol 2022;15:1031-44. [PMID: 36342412 DOI: 10.1080/17474086.2022.2144217] [Reference Citation Analysis]
|
| 5 |
Tremblay D, Baine I, Mascarenhas J. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide. Clin Lymphoma Myeloma Leuk 2022;22:e1067-74. [PMID: 36117043 DOI: 10.1016/j.clml.2022.08.011] [Reference Citation Analysis]
|
| 6 |
Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271 [DOI: 10.4240/wjgs.v14.i11.1260] [Reference Citation Analysis]
|
| 7 |
Mücke MM, Bruns T, Canbay A, Matzdorff A, Tacke F, Tiede A, Trebicka J, Wedemeyer H, Zacharowski K, Zeuzem S, Lange CM. Einsatz von Thrombopoetin-Rezeptor-Agonisten (TPO-RA) vor invasiven Eingriffen bei Patienten mit Leberzirrhose. Z Gastroenterol 2022. [DOI: 10.1055/a-1934-1867] [Reference Citation Analysis]
|
| 8 |
Ishikawa T, Ohashi K, Kodama E, Kobayashi T, Azumi M, Nozawa Y, Iwanaga A, Sano T, Honma T. Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis. Medicine (Baltimore) 2022;101:e30985. [PMID: 36221332 DOI: 10.1097/MD.0000000000030985] [Reference Citation Analysis]
|
| 9 |
Maevskaya MV, Zharkova MS, Ivashkin VT, Bessonova EN, Geyvandova NI, Kitsenko EA, Korochanskaya NV, Kurkina IA, Melikyan AL, Morozov VG, Khoronko YV. Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-70-82] [Reference Citation Analysis]
|
| 10 |
Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol 2022; 28(30): 4061-4074 [DOI: 10.3748/wjg.v28.i30.4061] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Orme ME, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, Yoshiji H, Agarwal K, Dusheiko G. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Adv Ther 2022. [PMID: 35836089 DOI: 10.1007/s12325-022-02235-w] [Reference Citation Analysis]
|
| 13 |
Song AB, Al-Samkari H. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Expert Rev Clin Immunol 2022. [PMID: 35793401 DOI: 10.1080/1744666X.2022.2098119] [Reference Citation Analysis]
|
| 14 |
Feng R, Liu Y, Zhu XL, Zhai WY, He Y, Fu HX, Jiang Q, Jiang H, Lu J, Liu H, Wang JW, Wang H, Xie YD, Ma H, Huang XJ, Zhang XH. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. J Viral Hepat 2022;29:306-16. [PMID: 35152507 DOI: 10.1111/jvh.13655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Shettar SS, Vandyck K, Tanaka KA. Coagulation Management in End-Stage Liver Disease. Curr Anesthesiol Rep. [DOI: 10.1007/s40140-022-00524-2] [Reference Citation Analysis]
|
| 16 |
Islam R, Kundu S, Jha SB, Rivera AP, Flores Monar GV, Islam H, Puttagunta SM, Sange I. Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management. Cureus. [DOI: 10.7759/cureus.23785] [Reference Citation Analysis]
|
| 17 |
Eguchi Y, Takahashi H, Mappa S, Santagostino E. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. Hepatol Res 2022;52:371-80. [PMID: 35134259 DOI: 10.1111/hepr.13755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Luther J, Friedman LS. Management of Thrombocytopenia and Coagulopathy in Patients with Chronic Liver Disease Undergoing Therapeutic Endoscopic Interventions. Clin Liver Dis 2022;26:1-12. [PMID: 34802655 DOI: 10.1016/j.cld.2021.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Gigante E, Sutter O, Nahon P, Seror O, Nault J. Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. Liver Cancer International 2022;3:37-46. [DOI: 10.1002/lci2.35] [Reference Citation Analysis]
|
| 20 |
Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, Shatzel JJ. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets 2022;33:66-72. [PMID: 33459573 DOI: 10.1080/09537104.2020.1859102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 21 |
Han X, Davis AM, Parker WF. Managing Adult Acute and Acute-on-Chronic Liver Failure in the ICU. JAMA 2021;326:1964-5. [PMID: 34783852 DOI: 10.1001/jama.2021.12742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev 2021;:100909. [PMID: 34815110 DOI: 10.1016/j.blre.2021.100909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021;161:1615-1627.e1. [PMID: 34579936 DOI: 10.1053/j.gastro.2021.08.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 24 |
Primignani M, Tosetti G, Tripodi A. Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded? Dig Liver Dis 2021;53:1394-5. [PMID: 34446353 DOI: 10.1016/j.dld.2021.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021;161:1630-56. [PMID: 34579937 DOI: 10.1053/j.gastro.2021.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 26 |
Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1396-403. [PMID: 34373229 DOI: 10.1016/j.dld.2021.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
Ronca V, Barabino M, Santambrogio R, Opocher E, Hodson J, Bertolini E, Birocchi S, Piccolo G, Battezzati P, Cattaneo M, Podda GM. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. Hepatol Commun 2021. [PMID: 34716696 DOI: 10.1002/hep4.1806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Primignani M, Tosetti G, Tripodi A. Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start? Dig Liver Dis 2021;53:1364-5. [PMID: 34210622 DOI: 10.1016/j.dld.2021.06.008] [Reference Citation Analysis]
|
| 29 |
Vipani A, Lindenmeyer CC, Sundaram V. Treatment of Severe Acute on Chronic Liver Failure: Management of Organ Failures, Investigational Therapeutics, and the Role of Liver Transplantation. J Clin Gastroenterol 2021;55:667-76. [PMID: 34028394 DOI: 10.1097/MCG.0000000000001568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 30 |
Sano Y, Morimoto M, Kobayashi S, Ueno M, Fukushima T, Asama H, Kawano K, Nagashima S, Tanaka S, Ohkawa S, Maeda S. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease. Digestion 2021;102:654-62. [PMID: 32841939 DOI: 10.1159/000509852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L, Wu A, Yang J, Qin D, Zou W, Wu J. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial. Front Pharmacol 2021;12:704093. [PMID: 34393785 DOI: 10.3389/fphar.2021.704093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Kawata Y, Endou M, Isozaki Y, Kitamura T, Fukushima Y, Sato T. Three cases of patients with chronic liver disease complicated by thrombocytopenia who were treated with lusutrombopag before tooth extraction. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 2021;33:463-6. [DOI: 10.1016/j.ajoms.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Ballantine A, Martin D, Thakrar SV. The coagulopathy of liver disease: a shift in thinking. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 34191571 DOI: 10.12968/hmed.2021.0111] [Reference Citation Analysis]
|
| 34 |
Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N. Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest 2021;51:e13503. [PMID: 33523482 DOI: 10.1111/eci.13503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 35 |
Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, Violi F; PReBRiC (Procedure-Related Bleeding Risk in Cirrhosis) group. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest 2021;51:e13508. [PMID: 33539542 DOI: 10.1111/eci.13508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 36 |
Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 37 |
Lim MY, Gilreath JA. Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization. Blood Adv 2020;4:4438-41. [PMID: 32936905 DOI: 10.1182/bloodadvances.2020003045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Scharf RE. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management. J Clin Med 2021;10:1530. [PMID: 33917431 DOI: 10.3390/jcm10071530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 39 |
Wang J, Dai M, Fu Q, Chen S. Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease. Sci Rep 2021;11:5459. [PMID: 33750817 DOI: 10.1038/s41598-021-84493-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Drolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer MH, Schramm C, Goeser T, Roesch T, Lohse AW, Kluwe J. Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis. Endoscopy 2021;53:226-34. [PMID: 32894867 DOI: 10.1055/a-1214-5355] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 41 |
Castelli R, Gidaro A, Lambertenghi Deliliers G. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures. Blood Coagul Fibrinolysis 2021;32:163-6. [PMID: 33555693 DOI: 10.1097/MBC.0000000000001001] [Reference Citation Analysis]
|
| 42 |
Yoshikawa Y, Kawaoka T, Andou Y, Kosaka Y, Suehiro Y, Uchikawa S, Nishida Y, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Imamura M, Aikata H, Chayama K. A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. Acta hepatologica Japonica 2021;62:136-143. [DOI: 10.2957/kanzo.62.136] [Reference Citation Analysis]
|
| 43 |
Delgado Ayala F, Ceballos Vázquez Tagle BG, Curiel Rivas JA, Díaz Greene EJ, Rodríguez Weber FL. Insuficiencia hepática aguda sobre crónica. Acta Médica Grupo Ángeles 2021;19:524-534. [DOI: 10.35366/102540] [Reference Citation Analysis]
|
| 44 |
Ozawa C, Yamaguchi N, Yoneyama F, Kimura K, Kato Y, Kouno H. A Case of Portal Vein/Superior Mesenteric Vein Thrombosis with Widespread Small Bowel Necrosis Possibly Caused by Oral Administration of Eltrombopag. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2021;82:2230-2234. [DOI: 10.3919/jjsa.82.2230] [Reference Citation Analysis]
|
| 45 |
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. [PMID: 33219529 DOI: 10.1002/hep.31646] [Cited by in Crossref: 171] [Cited by in F6Publishing: 166] [Article Influence: 85.5] [Reference Citation Analysis]
|
| 46 |
Tanaka KA, Chow J, Abuelkasem E. Liver Failure. Trauma Induced Coagulopathy 2021. [DOI: 10.1007/978-3-030-53606-0_37] [Reference Citation Analysis]
|
| 47 |
Solodovnikov AG, Sorokina EY, Morkovin EI. Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2020;10:236-243. [DOI: 10.30895/1991-2919-2020-10-4-236-243] [Reference Citation Analysis]
|
| 48 |
Chakraborty S, Alam S, Sayem M, Sanyal M, Das T, Saha P, Sayem M, Byapari BK, Tabassum CT, Kabir A, Amin MR, Nabi AHMN. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial. EClinicalMedicine 2020;29-30:100624. [PMID: 33294822 DOI: 10.1016/j.eclinm.2020.100624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Premkumar M, Sarin SK. Current Concepts in Coagulation Profile in Cirrhosis and Acute-on-Chronic Liver Failure. Clin Liver Dis (Hoboken) 2020;16:158-67. [PMID: 33163169 DOI: 10.1002/cld.976] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 50 |
Singh AD, Shalimar. Use of Blood Products and Drugs Before Procedures in Patients With Cirrhosis. Clin Liver Dis (Hoboken) 2020;16:153-7. [PMID: 33163168 DOI: 10.1002/cld.906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 51 |
Numata K, Tanaka K, Katsube T, Ochiai T, Fukuhara T, Kano T, Osaki Y, Izumi N, Imawari M. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study. Hepatol Res 2020;50:1141-50. [PMID: 32609920 DOI: 10.1111/hepr.13544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther 2020;52:1311-22. [PMID: 32813292 DOI: 10.1111/apt.16044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 53 |
Alkhouri N, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Trevisani F. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:2600-2608.e1. [PMID: 32205226 DOI: 10.1016/j.cgh.2020.03.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 54 |
Starlinger P, Luyendyk JP, Groeneveld DJ. Hemostasis and Liver Regeneration. Semin Thromb Hemost 2020;46:735-42. [PMID: 32906177 DOI: 10.1055/s-0040-1715450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 55 |
Katsube T, Shimizu R, Fukuhara T, Kano T, Wajima T. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clin Pharmacokinet 2019;58:1469-82. [PMID: 31055790 DOI: 10.1007/s40262-019-00770-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 56 |
Mohamed SE, Yassin MA. Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report. Case Rep Oncol 2020;13:863-6. [PMID: 32884532 DOI: 10.1159/000507987] [Reference Citation Analysis]
|
| 57 |
Suda T, Takatori H, Hayashi T, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Yamashita T, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Kaneko S. Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. Life (Basel) 2020;10:E177. [PMID: 32899804 DOI: 10.3390/life10090177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 58 |
Furuichi Y, Takeuchi H, Yoshimasu Y, Kasai Y, Abe M, Itoi T. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching. Hepatol Res 2020;50:1062-70. [PMID: 32510789 DOI: 10.1111/hepr.13530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 59 |
Nilles KM, Flamm SL. Thrombocytopenia in Chronic Liver Disease: New Management Strategies. Clin Liver Dis 2020;24:437-51. [PMID: 32620282 DOI: 10.1016/j.cld.2020.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 60 |
Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, Hubscher S, Karkhanis S, Lester W, Roslund N, West R, Wyatt JI, Heydtmann M. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut 2020;69:1382-403. [PMID: 32467090 DOI: 10.1136/gutjnl-2020-321299] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 61 |
Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol 2020;54:503-11. [PMID: 32195771 DOI: 10.1097/MCG.0000000000001338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 62 |
Qureshi K, Bonder A. Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease. World J Meta-Anal 2020; 8(3): 220-232 [DOI: 10.13105/wjma.v8.i3.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 63 |
Ozcelik F, Keskin U, Kılıçaslan E, Kale E. Laboratory Tests Used in the Diagnosis of Immune Thrombocytopenia and General Treatment Approaches. JHOR 2020;3:22-36. [DOI: 10.14302/issn.2372-6601.jhor-20-3372] [Reference Citation Analysis]
|
| 64 |
van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci 2020;21:E3294. [PMID: 32384725 DOI: 10.3390/ijms21093294] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 65 |
Rawi S, Wu GY. Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review. J Clin Transl Hepatol 2020;8:184-91. [PMID: 32832399 DOI: 10.14218/JCTH.2020.00007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 66 |
Chowdary P, Hamid C, Slatter D, Morris R, Foley JH, Gomez K, Brodkin E, Fox TA, Gatt A, McVey JH. Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro. Res Pract Thromb Haemost 2020;4:334-42. [PMID: 32110765 DOI: 10.1002/rth2.12310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 67 |
Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol 2020;2020:5421632. [PMID: 32047671 DOI: 10.1155/2020/5421632] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 68 |
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol 2020;115:18-40. [PMID: 31895720 DOI: 10.14309/ajg.0000000000000486] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 69 |
Moore AH. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. Clin Liver Dis (Hoboken) 2019;14:183-6. [PMID: 31879561 DOI: 10.1002/cld.860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 70 |
Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 71 |
Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology 2019;70:1336-48. [PMID: 30762895 DOI: 10.1002/hep.30561] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 72 |
Saab S, Brown RS Jr. Management of Thrombocytopenia in Patients with Chronic Liver Disease. Dig Dis Sci 2019;64:2757-68. [PMID: 31011942 DOI: 10.1007/s10620-019-05615-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 73 |
Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 2019;10:313-21. [PMID: 31565009 DOI: 10.2147/JBM.S191790] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 74 |
Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun 2019;3:1423-34. [PMID: 31701067 DOI: 10.1002/hep4.1423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 75 |
Li C, Li X, Huang F, Yang J, Wu A, Wang L, Qin D, Zou W, Wu J. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2019;10:829. [PMID: 31402863 DOI: 10.3389/fphar.2019.00829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 76 |
Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med 2019;18:596-604. [PMID: 31258695 DOI: 10.3892/etm.2019.7616] [Reference Citation Analysis]
|
| 77 |
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019;157:34-43.e1. [PMID: 30986390 DOI: 10.1053/j.gastro.2019.03.070] [Cited by in Crossref: 193] [Cited by in F6Publishing: 195] [Article Influence: 48.3] [Reference Citation Analysis]
|
| 78 |
Ryan L. Procedural Risk of Bleeding: Does the Management of Thrombocytopenia in Chronic Liver Disease Patients Make a Difference? A Debate. EMJ Hepatol 2019. [DOI: 10.33590/emjhepatol/10313853] [Reference Citation Analysis]
|
| 79 |
Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S, Wada H; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care 2019;7:32. [PMID: 31139417 DOI: 10.1186/s40560-019-0387-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 80 |
Ishikawa T, Okoshi M, Tomiyoshi K, Kojima Y, Horigome R, Imai M, Nozawa Y, Iwanaga A, Sano T, Honma T, Yoshida T. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res 2019;49:590-3. [PMID: 30602063 DOI: 10.1111/hepr.13305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 81 |
Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, Ishikawa T, Seike M, Katsube T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol 2019;17:1192-200. [PMID: 30502505 DOI: 10.1016/j.cgh.2018.11.047] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 82 |
Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 2019;10:2040620719841735. [PMID: 31007886 DOI: 10.1177/2040620719841735] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 83 |
Hoshino K, Harimoto N, Muranushi R, Araki K, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Yokobori T, Shirabe K. Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report. Surg Case Rep 2019;5:56. [PMID: 30969381 DOI: 10.1186/s40792-019-0619-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 84 |
Shirley M. Avatrombopag: First Global Approval. Drugs 2018;78:1163-8. [PMID: 29995177 DOI: 10.1007/s40265-018-0949-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 85 |
Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S. Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Ther Clin Risk Manag 2019;15:269-74. [PMID: 30804674 DOI: 10.2147/TCRM.S186106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 86 |
Weinberg EM. What Did We Learn From the ADAPT Trials? Gastroenterology 2019;156:824-5. [PMID: 30445011 DOI: 10.1053/j.gastro.2018.10.053] [Reference Citation Analysis]
|
| 87 |
Terrault NA, Hassanein TI. Reply. Gastroenterology 2019;156:825-6. [PMID: 30659833 DOI: 10.1053/j.gastro.2019.01.024] [Reference Citation Analysis]
|
| 88 |
Groeneveld D, Pereyra D, Veldhuis Z, Adelmeijer J, Ottens P, Kopec AK, Starlinger P, Lisman T, Luyendyk JP. Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans. Blood 2019;133:1245-56. [PMID: 30655274 DOI: 10.1182/blood-2018-08-869057] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 89 |
Sweeney JD. Patient Blood Management. Risk Management in Transfusion Medicine 2019. [DOI: 10.1016/b978-0-323-54837-3.00007-9] [Reference Citation Analysis]
|
| 90 |
Lisman T, Porte RJ. Understanding and Managing the Coagulopathy of Liver Disease. Consultative Hemostasis and Thrombosis 2019. [DOI: 10.1016/b978-0-323-46202-0.00036-4] [Reference Citation Analysis]
|
| 91 |
Kuter DJ. Thrombopoietin Receptor Agonists. Platelets 2019. [DOI: 10.1016/b978-0-12-813456-6.00061-8] [Reference Citation Analysis]
|
| 92 |
Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol 2019;54:171-81. [PMID: 30105510 DOI: 10.1007/s00535-018-1499-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 93 |
Mccafferty EH, Lyseng-williamson KA. Avatrombopag in the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure: a profile of its use in the USA. Drugs Ther Perspect 2019;35:1-6. [DOI: 10.1007/s40267-018-0593-0] [Reference Citation Analysis]
|
| 94 |
Scharf RE. Acquired Disorders of Platelet Function. Platelets 2019. [DOI: 10.1016/b978-0-12-813456-6.00049-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 95 |
Kuter DJ. General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. Consultative Hemostasis and Thrombosis 2019. [DOI: 10.1016/b978-0-323-46202-0.00007-8] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 96 |
Smith R. Coagulopathy in Cirrhotic Patients: Evaluation and Management. Multidisciplinary Approaches to Common Surgical Problems 2019. [DOI: 10.1007/978-3-030-12823-4_24] [Reference Citation Analysis]
|
| 97 |
Kushnir M, Billett HH. Hemostasis in Liver Disease. Transfusion Medicine and Hemostasis 2019. [DOI: 10.1016/b978-0-12-813726-0.00119-7] [Reference Citation Analysis]
|
| 98 |
Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. Dig Liver Dis 2019;51:24-7. [PMID: 29958825 DOI: 10.1016/j.dld.2018.06.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 99 |
Santos-sánchez OM. Evaluación del riesgo quirúrgico en pacientes con cirrosis hepática. Rev Colomb Gastroenterol 2018;33:431. [DOI: 10.22516/25007440.313] [Reference Citation Analysis]
|
| 100 |
Ma YR, Huang XJ, Mo XD, Han W, Yan CH, Chen Y, Ji Y, Chen YY, Wang Y, Zhang XH, Liu KY, Xu LP. [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2016;37:1065-9. [PMID: 28088971 DOI: 10.3760/cma.j.issn.0253-2727.2016.12.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 101 |
Sasaguri T, Hirakawa N, Uemura S. Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report. JA Clin Rep 2018;4:80. [PMID: 32025904 DOI: 10.1186/s40981-018-0217-7] [Reference Citation Analysis]
|
| 102 |
Estcourt LJ, Malouf R, Doree C, Trivella M, Hopewell S, Birchall J. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. Cochrane Database Syst Rev 2018;9:CD012779. [PMID: 30221749 DOI: 10.1002/14651858.CD012779.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 103 |
Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology 2018;155:705-18. [PMID: 29778606 DOI: 10.1053/j.gastro.2018.05.025] [Cited by in Crossref: 124] [Cited by in F6Publishing: 127] [Article Influence: 24.8] [Reference Citation Analysis]
|
| 104 |
Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F; faculty of the 7th International Coagulation in Liver Disease. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018;118:1491-1506. [PMID: 30060258 DOI: 10.1055/s-0038-1666861] [Cited by in Crossref: 96] [Cited by in F6Publishing: 82] [Article Influence: 19.2] [Reference Citation Analysis]
|
| 105 |
Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol 2018;68:783-97. [PMID: 29031662 DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 184] [Cited by in F6Publishing: 197] [Article Influence: 36.8] [Reference Citation Analysis]
|
| 106 |
Droc G. Thrombocytopenia in Liver Transplant. Thrombocytopenia 2018. [DOI: 10.5772/intechopen.72510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 107 |
Tapper EB, Afdhal NH. Noninvasive Assessment of Disease Progression. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00008-2] [Reference Citation Analysis]
|
| 108 |
Callum J, Janssen HLA, Dzik W. Hematologic Challenges in ICU Patients with Liver Disease and Gastrointestinal Hemorrhage. Hematologic Challenges in the Critically Ill 2018. [DOI: 10.1007/978-3-319-93572-0_9] [Reference Citation Analysis]
|
| 109 |
Hillis C, Lim W. Hematologic Manifestations of Liver Disease. Hematology 2018. [DOI: 10.1016/b978-0-323-35762-3.00153-0] [Reference Citation Analysis]
|
| 110 |
Kurokawa T, Ohkohchi N. Role of Platelet, Blood Stem Cell, and Thrombopoietin in Liver Regeneration, Liver Cirrhosis, and Liver Diseases. Stem Cells and Cancer in Hepatology 2018. [DOI: 10.1016/b978-0-12-812301-0.00009-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 111 |
Fujita M, Abe K, Hayashi M, Okai K, Takahashi A, Ohira H. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization. Fukushima J Med Sci 2017;63:165-71. [PMID: 29142151 DOI: 10.5387/fms.2017-07] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 112 |
Valla D. Vascular Liver Disease. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch33] [Reference Citation Analysis]
|
| 113 |
Zakeri N, Tsochatzis EA. Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep. 2017;19:45. [PMID: 28752476 DOI: 10.1007/s11894-017-0585-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 114 |
Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost 2017;1:150-61. [PMID: 30046685 DOI: 10.1002/rth2.12028] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 115 |
Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778-93. [PMID: 27860293 DOI: 10.1111/liv.13317] [Cited by in Crossref: 123] [Cited by in F6Publishing: 125] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 116 |
Lambert MP. Platelets in liver and renal disease. Hematology Am Soc Hematol Educ Program. 2016;2016:251-255. [PMID: 27913488 DOI: 10.1182/asheducation-2016.1.251] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 117 |
Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol 2017; 23(18): 3228-3239 [PMID: 28566882 DOI: 10.3748/wjg.v23.i18.3228] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 118 |
Gamoudi D, Cutajar M, Gamoudi N, Camilleri DJ, Gatt A. Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports. Clin Case Rep 2017;5:845-8. [PMID: 28588823 DOI: 10.1002/ccr3.946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 119 |
Sakamaki A, Watanabe T, Abe S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient. Clin J Gastroenterol 2017;10:261-4. [PMID: 28324272 DOI: 10.1007/s12328-017-0735-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 120 |
Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci 2017;3. [PMID: 30221012 DOI: 10.15761/JTS.1000182] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 121 |
Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol 2017;8:159-74. [PMID: 28473904 DOI: 10.1177/2040620717693573] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 122 |
Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing Concepts of Cirrhotic Coagulopathy. Am J Gastroenterol 2017;112:274-81. [PMID: 27801884 DOI: 10.1038/ajg.2016.498] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 123 |
Scharf RE. Acquired Disorders of Platelet Function. Platelets in Thrombotic and Non-Thrombotic Disorders 2017. [DOI: 10.1007/978-3-319-47462-5_64] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 124 |
Lisman T. Hemostatic and Non-hemostatic Functions of Platelets in Patients with Liver Disease. Platelets in Thrombotic and Non-Thrombotic Disorders 2017. [DOI: 10.1007/978-3-319-47462-5_78] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 125 |
Roberts LN, Patel RK, Arya R. Hepatology. Practical Hemostasis and Thrombosis 2016. [DOI: 10.1002/9781118344729.ch23] [Reference Citation Analysis]
|
| 126 |
Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther 2016;10:2833-43. [PMID: 27695288 DOI: 10.2147/DDDT.S95715] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 127 |
Maan R, de Knegt RJ, Veldt BJ. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 2015;75:1981-92. [PMID: 26501978 DOI: 10.1007/s40265-015-0480-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 128 |
González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 2016; 22(18): 4427-4437 [PMID: 27182154 DOI: 10.3748/wjg.v22.i18.4427] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 129 |
Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol 2016;91:E293-5. [PMID: 26910388 DOI: 10.1002/ajh.24341] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 130 |
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016;48:455-67. [PMID: 27012444 DOI: 10.1016/j.dld.2016.02.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 131 |
Kurokawa T, Zheng YW, Ohkohchi N. Novel functions of platelets in the liver. J Gastroenterol Hepatol 2016;31:745-51. [PMID: 26632220 DOI: 10.1111/jgh.13244] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 132 |
Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol 2016;64:717-35. [PMID: 26519602 DOI: 10.1016/j.jhep.2015.10.019] [Cited by in Crossref: 183] [Cited by in F6Publishing: 188] [Article Influence: 26.1] [Reference Citation Analysis]
|
| 133 |
Baumann AJ, Wheeler DS, Varadi G, Feyssa E. Severe Thrombotic Complication of Eltrombopag in a Cirrhotic Patient. ACG Case Reports Journal 2016;3:121-123. [DOI: 10.14309/crj.2016.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 134 |
Huntington SF, O’hara MH, Bennett JS. Platelet Disorders: Diagnostic Tests and Their Interpretations. Nonmalignant Hematology 2016. [DOI: 10.1007/978-3-319-30352-9_16] [Reference Citation Analysis]
|
| 135 |
Qureshi K, Patel S, Meillier A. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence. Int J Hepatol 2016;2016:1802932. [PMID: 27800187 DOI: 10.1155/2016/1802932] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 136 |
Neunert C. Acquired Platelet Disorders: Diagnosis and Management. Nonmalignant Hematology 2016. [DOI: 10.1007/978-3-319-30352-9_18] [Reference Citation Analysis]
|
| 137 |
Lozano M, Cid J. Alternative strategies to platelet transfusion. VOXS 2016;11:93-99. [DOI: 10.1111/voxs.12193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 138 |
Chavalitdhamrong D, Summerlee RJ, Draganov PV. Approach to Endoscopic Adverse Events. GI Endoscopic Emergencies 2016. [DOI: 10.1007/978-1-4939-3085-2_10] [Reference Citation Analysis]
|
| 139 |
Catalá-lópez F, Corrales I, de la Fuente-honrubia C, González-bermejo D, Martín-serrano G, Montero D, Saint-gerons DM. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Medicina Clínica (English Edition) 2015;145:511-519. [DOI: 10.1016/j.medcle.2015.03.001] [Reference Citation Analysis]
|
| 140 |
Debernardi Venon W, Ponzo P, Sacco M, Mengozzi G, Raso S, Valpreda A, Rizzetto M, Marzano A. Usefulness of thromboelastometry in predicting the risk of bleeding in cirrhotics who undergo invasive procedures. Eur J Gastroenterol Hepatol 2015;27:1313-9. [PMID: 26225869 DOI: 10.1097/MEG.0000000000000442] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 141 |
Kolb JM, Kaltenbach T, Martin B, Rouse RV, Soetikno R. Eltrombopag Use in Thrombocytopenia for Endoscopic Submucosal Dissection of a Gastric Carcinoid. ACG Case Rep J 2014;2:24-6. [PMID: 26157896 DOI: 10.14309/crj.2014.73] [Reference Citation Analysis]
|
| 142 |
Ikura Y, Osuga T. Changing common sense: Anti-platelet/coagulation therapy against cirrhosis. World J Hepatol 2015;7:1730-4. [PMID: 26167245 DOI: 10.4254/wjh.v7.i13.1730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 143 |
Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cherqui D, Castaing D, Azoulay D. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford) 2015;17:611-23. [PMID: 25980326 DOI: 10.1111/hpb.12416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 144 |
Qi X, De Stefano V, Guo X, Fan D. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs. Thromb Haemost 2015;113:1378-80. [PMID: 25761530 DOI: 10.1160/TH14-10-0892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 145 |
Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it? Liver Int 2015;35:1492-8. [PMID: 25312770 DOI: 10.1111/liv.12702] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 146 |
Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Managing complications in cirrhotic patients. United European Gastroenterol J 2015;3:80-94. [PMID: 25653862 DOI: 10.1177/2050640614560452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 147 |
Basit SA, Stone CD, Gish R. Portal vein thrombosis. Clin Liver Dis 2015;19:199-221. [PMID: 25454305 DOI: 10.1016/j.cld.2014.09.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 148 |
Haegele S, Offensperger F, Pereyra D, Lahner E, Assinger A, Fleischmann E, Gruenberger B, Gruenberger T, Brostjan C, Starlinger P. Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction. PLoS One 2015;10:e0116985. [PMID: 25611592 DOI: 10.1371/journal.pone.0116985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 149 |
Takeo T, Umino A, Miyashita H, Nakano Y, Yano M. THERAPY FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA PERFORMED SAFELY USING ELTROMBOPAG: A CASE OF COMPLICATED CHRONIC HEPATITIS C. JJTC 2015;61:463-467. [DOI: 10.3925/jjtc.61.463] [Reference Citation Analysis]
|
| 150 |
Qi X, Li H, Liu X, Yao H, Han G, Hu F, Shao L, Guo X. Novel insights into the development of portal vein thrombosis in cirrhosis patients. Expert Rev Gastroenterol Hepatol 2015;9:1421-32. [PMID: 26325361 DOI: 10.1586/17474124.2015.1083856] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 151 |
Valla DC, Rautou PE. The coagulation system in patients with end-stage liver disease. Liver Int 2015;35 Suppl 1:139-44. [PMID: 25529099 DOI: 10.1111/liv.12723] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 152 |
Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol. 2014;2:234-239. [PMID: 26357629 DOI: 10.14218/jcth.2014.00031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 153 |
Sharma V. Use of eltrombopag in thrombocytopenia of liver disease. World J Pharmacol 2014; 3(4): 186-192 [DOI: 10.5497/wjp.v3.i4.186] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 154 |
Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 2014;61:1253-9. [PMID: 25048952 DOI: 10.1016/j.jhep.2014.07.007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 155 |
Bissonnette J, Valla D, Rautou PE. Managing periprocedural thrombocytopenia in cirrhosis: aiming for a safety window. J Hepatol 2014;61:1199-201. [PMID: 25219886 DOI: 10.1016/j.jhep.2014.08.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 156 |
Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol 2014;77:532-44. [PMID: 24117976 DOI: 10.1111/bcp.12244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 157 |
Minowa K, Arai K, Kasahara M, Sakamoto S, Shimizu H, Nakano N, Ito R, Obayashi N, Nakazawa A, Ishiguro A. Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis. Pediatr Transplant 2014;18:E212-5. [PMID: 25041553 DOI: 10.1111/petr.12308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 158 |
Maan R, Veldt BJ, Janssen HL. Eltrombopag for thrombocytopenic patients with chronic HCV infection. Gastroenterology 2014;147:254-5. [PMID: 24877871 DOI: 10.1053/j.gastro.2014.01.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 159 |
Murata S, Maruyama T, Nowatari T, Takahashi K, Ohkohchi N. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis. Int J Mol Sci. 2014;15:5412-5425. [PMID: 24686514 DOI: 10.3390/ijms15045412] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 160 |
Kawaguchi T, Nakano M, Satani M, Sumie S, Yamada S, Amano K, Kuromatsu R, Sata M. Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncol Lett 2014;7:2130-4. [PMID: 24932302 DOI: 10.3892/ol.2014.1976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 161 |
Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol 2014; 20(10): 2595-2605 [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 162 |
Lee T, Huang J, Lee K, Lai C, Chen S, Kuo C. The use of platelet transfusion in thrombocytopenic patients for phacoemulsification. Taiwan Journal of Ophthalmology 2014;4:52-55. [DOI: 10.1016/j.tjo.2013.06.003] [Reference Citation Analysis]
|
| 163 |
Tripodi A, Primignani M, Mannucci PM. Reply to: is platelet transfusion necessary in cirrhotic patients with splenomegaly? Liver Int 2014;34:478-9. [PMID: 24119226 DOI: 10.1111/liv.12339] [Reference Citation Analysis]
|
| 164 |
Kinjo N, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, Nagao Y, Hashimoto N, Uehara H, Tomikawa M, Shirabe K, Maehara Y. Portal vein thrombosis in liver cirrhosis. World J Hepatol 2014;6:64-71. [PMID: 24575165 DOI: 10.4254/wjh.v6.i2.64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 165 |
Nowatari T, Murata S, Fukunaga K, Ohkohchi N. Role of platelets in chronic liver disease and acute liver injury. Hepatol Res 2014;44:165-72. [PMID: 23841688 DOI: 10.1111/hepr.12205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 166 |
Leber A, Feld JJ. Does eltrombopag really ENABLE SVR? Gastroenterology 2014;146:339-42. [PMID: 24361434 DOI: 10.1053/j.gastro.2013.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 167 |
Tripodi A. Should We Be Concerned About Coagulation in the Treatment of Acute Variceal Hemorrhage? Variceal Hemorrhage 2014. [DOI: 10.1007/978-1-4939-0002-2_15] [Reference Citation Analysis]
|
| 168 |
Giannini EG. Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. Future Virology 2014;9:9-20. [DOI: 10.2217/fvl.13.115] [Reference Citation Analysis]
|
| 169 |
Tapper EB, Robson SC, Malik R. Coagulopathy in cirrhosis - the role of the platelet in hemostasis. J Hepatol 2013;59:889-90. [PMID: 23669288 DOI: 10.1016/j.jhep.2013.03.040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 170 |
Wörmann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemother 2013;40:319-25. [PMID: 24273485 DOI: 10.1159/000355006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 171 |
Tripodi A, Primignani M. Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. Hepatology 2013;58:1177-80. [PMID: 23703879 DOI: 10.1002/hep.26502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 172 |
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98:10-23. [PMID: 23821332 DOI: 10.1007/s12185-013-1382-0] [Cited by in Crossref: 139] [Cited by in F6Publishing: 152] [Article Influence: 13.9] [Reference Citation Analysis]
|
| 173 |
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther 2013;37:1132-56. [PMID: 23638982 DOI: 10.1111/apt.12324] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 174 |
Danish FI, Yasmin S. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepat Med 2013;5:17-30. [PMID: 24696622 DOI: 10.2147/HMER.S27100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 175 |
Tripodi A, Primignani M, Chantarangkul V, Lemma L, Jovani M, Rebulla P, Mannucci PM. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int 2013;33:362-7. [PMID: 23231699 DOI: 10.1111/liv.12038] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 176 |
Giannini EG. Thrombocytopenia in patients with chronic liver disease: what's in a name? Dig Dis Sci 2013;58:299-301. [PMID: 23086124 DOI: 10.1007/s10620-012-2450-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 177 |
Arnold DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatr Blood Cancer 2013;60 Suppl 1:S19-22. [PMID: 23109488 DOI: 10.1002/pbc.24341] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
|
